Search
Search
About
Log in
Join
Experiences with
Idelalisib
Posts
Communities
141 public posts
Filter results
CMV PCR for blood <2.0E+2 IU/mL
I am in a clinical trial and am currently taking
Idelalisib
. The rest of my blood work is good. Jack
I am in a clinical trial and am currently taking
Idelalisib
. The rest of my blood work is good. Jack
rcusher
in
CLL Support
7 months ago
The CLL Medicine Cabinet - Choosing the Right Treatment for You
acalabrutinib - duvelisib - ibrutinib -
idelalisib
- pirtobrutinib - zanabrutinib rituximab - obinutuzumab - venetoclax - Learn More Managing Common Side Effects Chemoimmunotherapy Drug Types and Classes Clinical Trials
acalabrutinib - duvelisib - ibrutinib -
idelalisib
- pirtobrutinib - zanabrutinib rituximab - obinutuzumab - venetoclax - Learn More Managing Common Side Effects Chemoimmunotherapy Drug Types and Classes Clinical Trials
lankisterguy
Volunteer
in
CLL Support
6 months ago
Doctor mentioned Richters???
I am on the Bruin trial and was randomized to Arm B which is
Idelalisib
and Rituximab ( 6 months of infusions ). My bloodwork so far has shown slight improvement since the start in January of this year.
I am on the Bruin trial and was randomized to Arm B which is
Idelalisib
and Rituximab ( 6 months of infusions ). My bloodwork so far has shown slight improvement since the start in January of this year.
rcusher
in
CLL Support
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Optimal Treatment Combinations in the Management of CLL/SLL Jeff Sharman, MD Provided by Clinical Care Options, LLC
Moreso, the adverse events associated with
idelalisib
or duvelisib can be significant, especially with regard to grade 3 diarrhea or colitis.
Moreso, the adverse events associated with
idelalisib
or duvelisib can be significant, especially with regard to grade 3 diarrhea or colitis.
lankisterguy
Volunteer
in
CLL Support
1 year ago
Concise summary of the treatment history of CLL from the 1950s to the present, by Dr Bruce Cheson, contributor to the iwCLL and much more
well aware of this[i] "vacuum beyond BTKi and BCL-2 inhibition"[/i] and research is continuing into how modified use of PI3Ki drugs, such as intermittent dosing, can again gain the approval of the FDA for the use of later generation PI3Ki drugs such as duvelisib, umbralisib and zandelisib, now that
idelalisib
well aware of this[i] "vacuum beyond BTKi and BCL-2 inhibition"[/i] and research is continuing into how modified use of PI3Ki drugs, such as intermittent dosing, can again gain the approval of the FDA for the use of later generation PI3Ki drugs such as duvelisib, umbralisib and zandelisib, now that
idelalisib
AussieNeil
Administrator
in
CLL Support
1 year ago
Idelalisib
Has anybody got experience with
idelalisib
. Many thanks ☺️
Has anybody got experience with
idelalisib
. Many thanks ☺️
42828
in
CLL Support
2 years ago
PI3K inhibitors (idelalisib,copanlisib, duvelisib, parsaclisib, umbralisib, zandelisib, ACP-319) in CLL: where do we go from here?
However, the severe toxicity profile associated with the first-generation inhibitors
idelalisib
and duvelisib, combined with the availability of other more tolerable agents, have limited their use."
However, the severe toxicity profile associated with the first-generation inhibitors
idelalisib
and duvelisib, combined with the availability of other more tolerable agents, have limited their use."
CLLerinOz
Volunteer
in
CLL Support
2 years ago
Venetoclax second line treatment failing. (57yrs old)
Hi all, I was diagnosed in 2015 with CLL with 17p del & started
Idelalisib
at the Christie which got it under control for a few years until it failed. I was then put on Venetoclax which amazingly got me into remission but it has now started to fail.
Hi all, I was diagnosed in 2015 with CLL with 17p del & started
Idelalisib
at the Christie which got it under control for a few years until it failed. I was then put on Venetoclax which amazingly got me into remission but it has now started to fail.
spud2212
in
CLL Support
2 years ago
CLL Society ASH 2021 Highlights from Day 2 of ASH 2021! Dr. Brian Koffman gives up updates
Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus
Idelalisib
Brian Koffman gives up updates on the reversible non-covalently binding BTKi (Bruton’s tyrosine kinase inhibitor) pirtobrutinib (formerly LOXO-305), another reversable BTKi known as MK-1026 (formerly ARQ-531), 3-year follow-up data from the Ascend Trial: Acalabrutinib vs Rituximab plus
Idelalisib
bkoffman
CLL CURE Hero
in
CLL Support
2 years ago
tv ads for Leukemia drugs
this is why you are seeing ads for Leukemia drugs on tv .. this is from wikipedia ----"According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.[16]: 3, 7–8 Competition as well as potential for combination is expected from other drugs such as ibrutinib and
idelalisib
this is why you are seeing ads for Leukemia drugs on tv .. this is from wikipedia ----"According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.[16]: 3, 7–8 Competition as well as potential for combination is expected from other drugs such as ibrutinib and
idelalisib
craterlake
in
CLL Support
2 years ago
Ibrutinib Resistance
Is that the right approach or should she switch to Venetoclax or
Idelalisib
/Duvelisib? Any insight you have is very helpful. Thank you
Is that the right approach or should she switch to Venetoclax or
Idelalisib
/Duvelisib? Any insight you have is very helpful. Thank you
Adel1
in
CLL Support
2 years ago
OncLive 9 CLL Videos - Optimizing the Treatment of CLL With Novel Therapies and more Take-home messages from ASH 2021
. - PI3K Inhibitors for CLL March 7th 2022 https://www.onclive.com/view/pi3k-inhibitors-for-cll A comparison of 3 PI3K inhibitors—
idelalisib
, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia. - Noncovalent BTK Inhibitors in CLL March 7th 2022 https://www.onclive.com/view/noncovalent-btk-inhibitors-in-cll
. - PI3K Inhibitors for CLL March 7th 2022 https://www.onclive.com/view/pi3k-inhibitors-for-cll A comparison of 3 PI3K inhibitors—
idelalisib
, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia. - Noncovalent BTK Inhibitors in CLL March 7th 2022 https://www.onclive.com/view/noncovalent-btk-inhibitors-in-cll
lankisterguy
Volunteer
in
CLL Support
2 years ago
Have you relapsed on, or become refractory to a Btki drug such as ibrutinib, or the bcl-2i venetoclax?
However, when patients relapse or become refractory to these, the approved PI3Kinase inhibitors duvelisib or
idelalisib
, and the still-experimental umbralisib offer potent and potentially helpful third options. Side effects of PI3ks have made some patients apprehensive.
However, when patients relapse or become refractory to these, the approved PI3Kinase inhibitors duvelisib or
idelalisib
, and the still-experimental umbralisib offer potent and potentially helpful third options. Side effects of PI3ks have made some patients apprehensive.
bkoffman
CLL CURE Hero
in
CLL Support
3 years ago
Short Update on Ibrutinib + Idelalisib + Venetoclax "N of 1" trial after lower dose.
A update on my very surprising results when combining Ibrutinib +
Idelalisib
+ Venetoclax. Initial Post with more detail: https://healthunlocked.com/cllsupport/posts/145327977/my-n-of-1-trial-with-ibrutinib-
idelalisib
-venetoclax-that-lead-to-remission-of-richters-in-three-weeks.
A update on my very surprising results when combining Ibrutinib +
Idelalisib
+ Venetoclax. Initial Post with more detail: https://healthunlocked.com/cllsupport/posts/145327977/my-n-of-1-trial-with-ibrutinib-
idelalisib
-venetoclax-that-lead-to-remission-of-richters-in-three-weeks.
UniversallyPersonal
in
CLL Support
3 years ago
My "N of 1" trial with Ibrutinib + Idelalisib + Venetoclax that lead to remission of Richter's in three weeks.
I started with 2x150mg
Idelalisib
+ 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg
Idelalisib
, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.
I started with 2x150mg
Idelalisib
+ 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg
Idelalisib
, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.
UniversallyPersonal
in
CLL Support
3 years ago
Richter’s Transformation - Update 27-01-2021
I started with 2x150mg
Idelalisib
+ 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg
Idelalisib
, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.
I started with 2x150mg
Idelalisib
+ 280mg Ibrutinib + 200mg Venetoclax. This is now lowered to 2x150mg
Idelalisib
, 140mg Ibrutinib, 100mg Venteoclax pr day, the bone marrow is still suppressed on this combination and it would not be a good treatment long term.
Priss69
in
CLL Support
3 years ago
Resistance-Associated Mutations in CLL Patients Treated With Novel Agents
No common resistance-associated mutations or deregulated signaling pathways have been reported in
idelalisib
failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax. For 20% of patients, the ibrutinib resistance-associated mutations remain unknown.
No common resistance-associated mutations or deregulated signaling pathways have been reported in
idelalisib
failure. Acquired mutations in the BCL2 gene were detected in patients who had failed on venetoclax. For 20% of patients, the ibrutinib resistance-associated mutations remain unknown.
Jm954
Administrator
in
CLL Support
4 years ago
Imbruvica-related issues: Qs + comments
* What about
Idelalisib
, which I’ve read is well tolerated? * If I were to discontinue Imbruvica, which other drug would you recommend? Whichever it might be, I’d like to start at a lower dose than typically recommended. * What do you think of CBD oil for my agitation?
* What about
Idelalisib
, which I’ve read is well tolerated? * If I were to discontinue Imbruvica, which other drug would you recommend? Whichever it might be, I’d like to start at a lower dose than typically recommended. * What do you think of CBD oil for my agitation?
Pogee
in
CLL Support
4 years ago
ASCEND: Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Take home message is that Acalabrutinib significantly improved PFS and that
Plus Rituximab treatment was associated with a high level of serious adverse events compared to the other treatments.
Take home message is that Acalabrutinib significantly improved PFS and that
Plus Rituximab treatment was associated with a high level of serious adverse events compared to the other treatments.
Jm954
Administrator
in
CLL Support
4 years ago
Real-World Sequence Patterns of Novel Agents in CLL
Treatment sequencing and clinical responses after treatment with BCL-2 inhibitor venetoclax, or novel agents in the B-cell receptor pathway inhibitor (BCRi) class such as ibrutinib,
idelalisib
, acalabrutinib, or another novel BCRi medication, were assessed.
Treatment sequencing and clinical responses after treatment with BCL-2 inhibitor venetoclax, or novel agents in the B-cell receptor pathway inhibitor (BCRi) class such as ibrutinib,
idelalisib
, acalabrutinib, or another novel BCRi medication, were assessed.
Jm954
Administrator
in
CLL Support
4 years ago
1
2
...
8
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
131 results
Non Hodgkin's Lymphoma Friends
6 results
Advanced Prostate Cancer
1 result
View top 10 communities
Sort by
Most Relevant
Newest